Published in J Virol on April 21, 2010
Restriction of diverse retroviruses by SAMHD1. Retrovirology (2013) 1.23
Alpharetroviral self-inactivating vectors: long-term transgene expression in murine hematopoietic cells and low genotoxicity. Mol Ther (2012) 0.98
Gammaretroviral vectors: biology, technology and application. Viruses (2011) 0.91
Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity. Nat Biotechnol (2016) 0.90
Development of gene therapy for blood disorders: an update. Blood (2013) 0.90
Alpharetroviral vector-mediated gene therapy for X-CGD: functional correction and lack of aberrant splicing. Mol Ther (2012) 0.88
Cancer gene discovery: exploiting insertional mutagenesis. Mol Cancer Res (2013) 0.88
Perinatal gene transfer to the liver. Curr Pharm Des (2011) 0.84
The retroviral vector family: something for everyone. Virus Genes (2017) 0.83
Genome-wide analysis of alpharetroviral integration in human hematopoietic stem/progenitor cells. Genes (Basel) (2014) 0.78
Alpharetroviral vectors: from a cancer-causing agent to a useful tool for human gene therapy. Viruses (2014) 0.77
An assessment of the effects of ectopic gp91phox expression in XCGD iPSC-derived neutrophils. Mol Ther Methods Clin Dev (2015) 0.77
Detailed comparison of retroviral vectors and promoter configurations for stable and high transgene expression in human induced pluripotent stem cells. Gene Ther (2017) 0.75
Application of Droplet Digital PCR for Estimating Vector Copy Number States in Stem Cell Gene Therapy. Hum Gene Ther Methods (2016) 0.75
The interferon-inducible antiviral protein Daxx is not essential for interferon-mediated protection against avian sarcoma virus. Virol J (2014) 0.75
Generation of Genetically Engineered Precursor T-Cells From Human Umbilical Cord Blood Using an Optimized Alpharetroviral Vector Platform. Mol Ther (2016) 0.75
Genetic Modification of T Cells. Biomedicines (2016) 0.75
A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res (2001) 124.61
A third-generation lentivirus vector with a conditional packaging system. J Virol (1998) 16.07
HIV-1 integration in the human genome favors active genes and local hotspots. Cell (2002) 12.60
Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther (2000) 12.54
Transcription start regions in the human genome are favored targets for MLV integration. Science (2003) 12.21
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest (2008) 9.42
Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol (2004) 8.27
Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol (1998) 8.21
Signals for ribosomal frameshifting in the Rous sarcoma virus gag-pol region. Cell (1988) 7.14
A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res (1995) 7.08
Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest (2008) 7.05
Adaptor plasmids simplify the insertion of foreign DNA into helper-independent retroviral vectors. J Virol (1987) 6.88
Generation of high-titer pseudotyped retroviral vectors with very broad host range. Methods Cell Biol (1994) 5.17
The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest (2009) 3.34
cis-Acting RNA packaging locus in the 115-nucleotide direct repeat of Rous sarcoma virus. J Virol (1983) 3.34
Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood (2006) 3.07
Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther (2009) 2.56
Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol Ther (2008) 2.56
Mutagenesis of the region between env and src of the SR-A strain of Rous sarcoma virus for the purpose of constructing helper-independent vectors. Virology (1984) 2.38
Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J Exp Med (1992) 2.12
Lentiviral vectors pseudotyped with murine ecotropic envelope: increased biosafety and convenience in preclinical research. Exp Hematol (2006) 1.95
Avian retroviral RNA element promotes unspliced RNA accumulation in the cytoplasm. J Virol (1996) 1.85
Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells. Mol Ther (2005) 1.82
Oncoretrovirus and lentivirus vectors pseudotyped with lymphocytic choriomeningitis virus glycoprotein: generation, concentration, and broad host range. J Virol (2002) 1.74
Evolutionary conservation of a 2-kb intronic sequence flanking a tissue-specific alternative exon in the PTBP2 gene. Genomics (2004) 1.56
Enhancer activity correlates with the oncogenic potential of avian retroviruses. EMBO J (1985) 1.52
The RCAS vector system. Folia Biol (Praha) (2004) 1.48
Avian sarcoma virus gag precursor polypeptide is not processed in mammalian cells. J Virol (1982) 1.46
Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency. Mol Ther (2008) 1.44
Overcoming promoter competition in packaging cells improves production of self-inactivating retroviral vectors. Gene Ther (2006) 1.44
Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells. J Virol (1995) 1.42
Woodchuck hepatitis virus post-transcriptional regulatory element deleted from X protein and promoter sequences enhances retroviral vector titer and expression. Gene Ther (2006) 1.39
Insertional gene activation by lentiviral and gammaretroviral vectors. J Virol (2008) 1.35
Dose finding with retroviral vectors: correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population. Blood (2003) 1.34
Autogenous regulation of RNA translation and packaging by Rous sarcoma virus Pr76gag. J Virol (1996) 1.27
Pois(s)on--it's a question of dose... Gene Ther (2004) 1.23
Generation of RCAS vectors useful for functional genomic analyses. DNA Res (2001) 1.23
Secondary structure and mutational analysis of the ribosomal frameshift signal of rous sarcoma virus. J Mol Biol (1998) 1.12
Reduced genotoxicity of avian sarcoma leukosis virus vectors in rhesus long-term repopulating cells compared to standard murine retrovirus vectors. Mol Ther (2008) 1.12
Concerted action of multiple cis-acting sequences is required for Rev dependence of late human immunodeficiency virus type 1 gene expression. J Virol (2000) 1.08
Influence of multiplicity of infection and protein stability on retroviral vector-mediated gene expression in hematopoietic cells. Gene Ther (2001) 1.08
Integrated self-inactivating lentiviral vectors produce full-length genomic transcripts competent for encapsidation and integration. J Virol (2004) 1.06
Mechanisms controlling titer and expression of bidirectional lentiviral and gammaretroviral vectors. Gene Ther (2009) 0.93
Transduction of rhesus macaque hematopoietic stem and progenitor cells with avian sarcoma and leukosis virus vectors. Hum Gene Ther (2007) 0.89
Foamy virus vectors for gene transfer. Expert Opin Biol Ther (2009) 0.88
Murine leukemia induced by retroviral gene marking. Science (2002) 3.59
Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science (2005) 3.58
A differentiation checkpoint limits hematopoietic stem cell self-renewal in response to DNA damage. Cell (2012) 3.21
Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood (2006) 3.07
Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol Ther (2008) 2.56
Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther (2009) 2.56
Resistance of mature T cells to oncogene transformation. Blood (2008) 2.32
Overcoming reprogramming resistance of Fanconi anemia cells. Blood (2012) 2.07
Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity. Sci Transl Med (2014) 2.00
Retroviral vector insertion sites associated with dominant hematopoietic clones mark "stemness" pathways. Blood (2006) 1.98
Lentiviral vectors pseudotyped with murine ecotropic envelope: increased biosafety and convenience in preclinical research. Exp Hematol (2006) 1.95
The phenotype of human STK4 deficiency. Blood (2012) 1.84
Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood (2005) 1.82
Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells. Mol Ther (2005) 1.82
Lentiviral vector design and imaging approaches to visualize the early stages of cellular reprogramming. Mol Ther (2011) 1.69
NAMPT is essential for the G-CSF-induced myeloid differentiation via a NAD(+)-sirtuin-1-dependent pathway. Nat Med (2009) 1.66
HOXB4 enforces equivalent fates of ES-cell-derived and adult hematopoietic cells. Proc Natl Acad Sci U S A (2005) 1.65
Pharmacological targeting of the thrombomodulin-activated protein C pathway mitigates radiation toxicity. Nat Med (2012) 1.58
Gene therapy: X-SCID transgene leukaemogenicity. Nature (2006) 1.57
T-cell receptor gene transfer exclusively to human CD8(+) cells enhances tumor cell killing. Blood (2012) 1.55
Hepatic lentiviral gene transfer is associated with clonal selection, but not with tumor formation in serially transplanted rodents. Hepatology (2013) 1.55
LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropenia. Nat Med (2006) 1.52
Genotoxic potential of lineage-specific lentivirus vectors carrying the beta-globin locus control region. Mol Ther (2009) 1.46
Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency. Mol Ther (2008) 1.44
Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. Mol Ther (2007) 1.44
Upstream conserved sequences of mouse leukemia viruses are important for high transgene expression in lymphoid and hematopoietic cells. Mol Ther (2002) 1.44
Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J Virol (2004) 1.43
Retroviral vectors for high-level transgene expression in T lymphocytes. Hum Gene Ther (2003) 1.43
Medicine. Gene therapy--new challenges ahead. Science (2003) 1.43
HOXB4's road map to stem cell expansion. Proc Natl Acad Sci U S A (2007) 1.43
Improving transcriptional termination of self-inactivating gamma-retroviral and lentiviral vectors. Mol Ther (2007) 1.42
A modified γ-retrovirus vector for X-linked severe combined immunodeficiency. N Engl J Med (2014) 1.42
Loss-of-function mutations in the IL-21 receptor gene cause a primary immunodeficiency syndrome. J Exp Med (2013) 1.39
Transcriptional enhancers induce insertional gene deregulation independently from the vector type and design. Mol Ther (2009) 1.39
Recombinase-mediated cassette exchange (RMCE): traditional concepts and current challenges. J Mol Biol (2011) 1.38
MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML. Blood (2007) 1.37
Dose finding with retroviral vectors: correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population. Blood (2003) 1.34
Bromo- and extraterminal domain chromatin regulators serve as cofactors for murine leukemia virus integration. J Virol (2013) 1.34
Protein transduction from retroviral Gag precursors. Proc Natl Acad Sci U S A (2010) 1.30
Mice with ribosomal protein S19 deficiency develop bone marrow failure and symptoms like patients with Diamond-Blackfan anemia. Blood (2011) 1.28
Preparation of bioactive soluble human leukemia inhibitory factor from recombinant Escherichia coli using thioredoxin as fusion partner. Protein Expr Purif (2010) 1.22
Cell-intrinsic and vector-related properties cooperate to determine the incidence and consequences of insertional mutagenesis. Mol Ther (2009) 1.21
Rescue of ATP7B function in hepatocyte-like cells from Wilson's disease induced pluripotent stem cells using gene therapy or the chaperone drug curcumin. Hum Mol Genet (2011) 1.20
Predictable and efficient retroviral gene transfer into murine bone marrow repopulating cells using a defined vector dose. Exp Hematol (2003) 1.16
Tumor cells escape suicide gene therapy by genetic and epigenetic instability. Blood (2004) 1.11
miR-99a/100~125b tricistrons regulate hematopoietic stem and progenitor cell homeostasis by shifting the balance between TGFβ and Wnt signaling. Genes Dev (2014) 1.11
Gene therapy on the move. EMBO Mol Med (2013) 1.10
A ubiquitous chromatin opening element prevents transgene silencing in pluripotent stem cells and their differentiated progeny. Stem Cells (2013) 1.09
Highly significant antiviral activity of HIV-1 LTR-specific tre-recombinase in humanized mice. PLoS Pathog (2013) 1.08
Clinical application of lentiviral vectors - concepts and practice. Curr Gene Ther (2008) 1.07
Ectopic HOXB4 overcomes the inhibitory effect of tumor necrosis factor-{alpha} on Fanconi anemia hematopoietic stem and progenitor cells. Blood (2009) 1.07
Optimal reprogramming factor stoichiometry increases colony numbers and affects molecular characteristics of murine induced pluripotent stem cells. Cytometry A (2011) 1.05
The influence of semen-derived enhancer of virus infection on the efficiency of retroviral gene transfer. J Gene Med (2010) 1.05
Unmodified Cre recombinase crosses the membrane. Nucleic Acids Res (2002) 1.04
Insertion sites in engrafted cells cluster within a limited repertoire of genomic areas after gammaretroviral vector gene therapy. Mol Ther (2011) 1.04
Development of novel efficient SIN vectors with improved safety features for Wiskott-Aldrich syndrome stem cell based gene therapy. Mol Pharm (2011) 1.03
Rapid lentiviral transduction preserves the engraftment potential of Fanca(-/-) hematopoietic stem cells. Mol Ther (2008) 1.02
Retroviral pseudotransduction for targeted cell manipulation. Mol Cell (2004) 1.02
Generation of healthy mice from gene-corrected disease-specific induced pluripotent stem cells. PLoS Biol (2011) 1.02
Inherited DOCK2 Deficiency in Patients with Early-Onset Invasive Infections. N Engl J Med (2015) 1.02
Lentiviral vector induced insertional haploinsufficiency of Ebf1 causes murine leukemia. Mol Ther (2012) 1.01
Murine embryonic stem cell-derived hepatic progenitor cells engraft in recipient livers with limited capacity of liver tissue formation. Cell Transplant (2008) 1.01
Biosafety features of lentiviral vectors. Hum Gene Ther (2013) 1.01
Modeling abnormal early development with induced pluripotent stem cells from aneuploid syndromes. Hum Mol Genet (2011) 1.00
Retrovirus vectors: toward the plentivirus? Mol Ther (2006) 1.00
State-of-the-art lentiviral vectors for research use: risk assessment and biosafety recommendations. Curr Gene Ther (2009) 1.00